Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial
Jean Y. Tang, M. Peter Marinkovich, Karen Wiss, Daniel McCarthy, A. Truesdale, Albert S. Chiou, Edward Eid, Joyce K. McIntyre, Irene Bailey, Louise K. Furukawa, Emily S. Gorell, Nicki Harris, Rohit K. Khosla, H. Peter Lorenz, Ying Lü, Jaron Nazaroff, I Dmitriy Grachev, Amanda J Moore
Topics & Concepts
Epidermolysis bullosaDermatologyMedicineOpen labelRandomized controlled trialSurgerySkin and Cellular Biology ResearchDermatological and Skeletal DisordersAutoimmune Bullous Skin Diseases